- Home
- SJT vs EDIT Comparison
SJT vs EDIT Comparison
Compare SJT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- EDIT
- Stock Information
- Founded
- SJT 1980
- EDIT 2013
- Country
- SJT United States
- EDIT United States
- Employees
- SJT N/A
- EDIT N/A
- Industry
- SJT Oil & Gas Production
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SJT Energy
- EDIT Health Care
- Exchange
- SJT Nasdaq
- EDIT Nasdaq
- Market Cap
- SJT 269.4M
- EDIT 269.8M
- IPO Year
- SJT N/A
- EDIT 2016
- Fundamental
- Price
- SJT $5.87
- EDIT $2.85
- Analyst Decision
- SJT
- EDIT Buy
- Analyst Count
- SJT 0
- EDIT 11
- Target Price
- SJT N/A
- EDIT $4.56
- AVG Volume (30 Days)
- SJT 249.1K
- EDIT 3.0M
- Earning Date
- SJT 11-14-2025
- EDIT 10-31-2025
- Dividend Yield
- SJT N/A
- EDIT N/A
- EPS Growth
- SJT N/A
- EDIT N/A
- EPS
- SJT N/A
- EDIT N/A
- Revenue
- SJT $42,635.00
- EDIT $38,901,000.00
- Revenue This Year
- SJT N/A
- EDIT N/A
- Revenue Next Year
- SJT N/A
- EDIT N/A
- P/E Ratio
- SJT N/A
- EDIT N/A
- Revenue Growth
- SJT N/A
- EDIT N/A
- 52 Week Low
- SJT $3.66
- EDIT $0.91
- 52 Week High
- SJT $7.22
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- SJT 54.10
- EDIT 37.61
- Support Level
- SJT $5.38
- EDIT $2.94
- Resistance Level
- SJT $5.98
- EDIT $3.37
- Average True Range (ATR)
- SJT 0.24
- EDIT 0.29
- MACD
- SJT 0.03
- EDIT -0.13
- Stochastic Oscillator
- SJT 82.67
- EDIT 1.00
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.